This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
NEW YORK ( TheStreet) -- The earnings woodshed is getting crowded as Avon Products(AVP - Get Report) led 10 companies to the woodshed last week. Among these stocks Avon was the only one of the 10 that was upgraded to buy on its share price weakness.
Buy-And-Trade Parameters from the Woodshed
Avon Products ($17.74) missed EPS estimates by 5 cents earning 14 cents a share premarket on Thursday. The stock closed at $22.40 on Wednesday and crashed below its 50-day and 200-day simple moving averages at $20.64 and $21.12 to a low of $17.02 on Thursday. Share price weakness resulted in an upgrade to buy from hold according to www.ValuEngine.com. The maker of beauty products has an annual value level at $12.83 with a quarterly pivot at $17.36, a semiannual pivot at $19.81 and weekly risky level at $21.05.
Boyd Gaming(BYD) ($10.21) missed EPS estimates by 9 cents reporting a loss of 8 cents a share in premarket trading on Thursday. The stock plunged from $12.98 at the close on Wednesday to a low of $10.11 on Monday well below its 200-day SMA at $10.88. The hold rated gaming company has a semiannual value level at $9.29 with a quarterly risky level at $13.78.
Con-way(CNW) ($41.73) missed EPS estimates by 4 cents earning 58 cents a share in afterhours trading on Wednesday. The sell rated trucker detoured to the woodshed as the stock plunged below its 50-day SMA at $43.42 to a low of $40.15 on Thursday. The 200-day SMA is $38.74 with a semiannual pivot at $41.77 and monthly risky level at $43.63.
Crocs(CROX) ($12.45) missed EPS estimates by a penny earning 17 cents a share in afterhours trading on Wednesday. By the end of last week the hold rated maker of colorful footwear set a new 52-week low at $11.96. My quarterly value level is $7.64 with a weekly pivot at $13.04 and a monthly risky level at $13.75.
Novo Nordisk(NVO) ($168.42) reported quarterly results on Thursday earning $2.20 per share. The buy rated pharmaceutical company that concentrates on products for the treatment of diabetes fell below its 50-day and 200-day SMAs at $170.09 and $169.88 with a monthly value level at $156.69 and a semiannual risky level at $174.38.